In support of anti-PD-L1 therapy significantly enhancing tumour reduction and prolonging survival of tumour-bearing mice by augmenting the HDAC inhibitor modulation of the M1 TAM response detailed above [268], PD-1 blockage has also been shown to be effective at aiding the expansion and prolonged potency of CAR T therapy [282]. This evidence concerns the gene CD274 and neoplasm.